http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-6142098-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-665 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65586 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2016-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2017-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2017-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-6142098-B1 |
titleOfInvention | 5-azacytidine or its 2'-deoxy 5'-position dibenzyl phosphate |
abstract | [PROBLEMS] To replace oral injections (5-azacytidine and 2′-deoxy-5-azacytidine) which are clinically used as therapeutic agents for bone marrow tumors, have high stability with respect to the metabolic enzyme cytidine deaminase, and are orally administered. However, to provide a drug that is absorbed into the body and incorporated into RNA and DNA biosynthetic pathways to inhibit protein synthesis. [Solution] Formula (1): A novel compound represented by the formula (wherein R is a hydroxyl group or a hydrogen atom, and R 1 and R 2 are each a benzyl group optionally having a substituent) has solved the above problems. [Selection figure] None |
priorityDate | 2015-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 209.